Persistent selling steers Tilray stock lower, limiting further downside

Traders Union
All News
Financial News
Tilray drops 3.02% after HelloMD deal

Highlights

Tilray's acquisition of HelloMD’s Canadian assets integrates a digital health platform, expanding its medical cannabis offerings and patient engagement.
The deal supports development of a fully vertically integrated medical cannabis framework and solidifies Tilray’s telehealth capabilities in Canada.
Shares remain under persistent selling pressure with a strong bearish trend; $4.32 is key support and $4.59 immediate resistance, with downside favored in the near term.

Digital platform expansion accelerates as medical cannabis integration advances

Tilray Brands has announced the acquisition of HelloMD Corporation’s Canadian medical cannabis assets, which according to Investing, brings a digital healthcare and patient engagement platform into its medical marijuana operations. This move is set to expand Tilray’s reach by integrating telehealth consultation services and educational resources, broadening both access channels and service offerings for Canadian patients. As reported by Manilatimes, the acquisition will support the development of a fully vertically integrated medical cannabis framework and bolster Tilray’s digital healthcare capabilities, though price action has remained under broader selling pressure.

Technical momentum weakens as sell signals dominate below resistance

On the technical front, TLRY trades below the 20-period ($4.55) and 50-period ($4.61) moving averages on the 1-hour chart, as well as below the 200-period ($8.93) moving average on the daily timeframe. The Ichimoku Kijun on the daily chart marks immediate resistance at $4.59. Among momentum indicators, Moving Average Convergence Divergence (MACD) registers a strong sell, while Average Directional Index (ADX) is neutral. Relative Strength Index (RSI) is at 44.54, giving a sell signal, and Stochastic RSI is in oversold territory. Commodity Channel Index (CCI) and Awesome Oscillator remain neutral, and Bull/Bear Power points to dominant intraday selling.

Range-bound outlook persists amid low breakout probability

For the next several sessions, TLRY is expected to trade within a range of $4.32 to $4.62 as defined by recent volatility. The probability of an upside breakout is very low, with a strong likelihood that price will remain subdued. The baseline scenario calls for continued range-bound action; a bullish reversal would require a break above the $4.59 resistance, while a move below $4.32 support would mark a bearish extension.

Viktoras Karapetjanc, expert at Traders Union, notes that Tilray’s acquisition of HelloMD’s Canadian assets is a key step in strengthening its digital and vertical integration in medical cannabis. He sees the company’s operational capabilities and patient access improving as a result, which could help sentiment over the medium term. Technically, however, the stock remains under seller pressure with little immediate prospect of a breakout above key resistance. Karapetjanc believes sentiment could shift positively if the new integration translates into clear operational growth. "I see fundamental progress taking shape, and if the market recognizes these efforts, confidence in Tilray could be restored from these lower levels."

Earlier, analysts noted that Tilray’s stabilization above certain technical benchmarks was creating a near-term pivot point despite underlying bearish sentiment in the stock. The latest decline beneath key moving averages and subdued momentum indicators underscores persistent downside risk, making a sustained move above the $4.59 resistance essential for any meaningful bullish reversal.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.